Longmont, United States
KromaTiD®, established in 2007, operates in the Biotechnology and Platforms sectors, with its headquarters in the United States. The company stands out with its slogan, "Direct, Definitive Genomics," which encapsulates its mission to provide cutting-edge consultative solutions for high-resolution, single-cell cytogenetic analysis. These solutions are pivotal for advancing modern innovations in cell and gene therapy.
The company recently secured a $4.88M Series C investment on 28 November 2023, showcasing investor confidence in its business model and growth trajectory. While the specific investors for this round remain undisclosed, this funding infusion signals market validation and supports KromaTiD®’s expansion capabilities and technological advancements. As the company continues to innovate and deepen its impact in the genomics domain, it presents a compelling growth opportunity for investors seeking to capitalize on the increasing demand for precision medicine solutions.
Rubik Therapeutics